The presence of a large number of activated phenotypes of plasmacytoid DCs suggests that CD4 effector T cells may promote anti-tumor immunity by enhancing the ability of DCs to induce CD8 T cell responses and directly promoting the expansion of CD8 T cells [57,58]. The gene discussed is CD8A; the disease is neoplasm.